Clinical Trials · NCT03902951

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Active Not RecruitingPhase 2Gonadorelin (Investigational)
Phase
Phase 2
Recruitment status
Active Not Recruiting
Sponsor
Jonsson Comprehensive Cancer Center
Enrollment
28
Start date
Mar 2021
Locations
1 site, United States
Primary endpoint
Percent of patients achieving a serum prostate specific antigen (PSA) of < 0.05 ng/mL
View Gonadorelin compound reference